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Abstract
HIV-infected U.S. adults have reported internalized HIV-related stigma; however, the national 
prevalence of stigma is unknown. We sought to determine HIV-related stigma prevalence among 
adults in care, describe which socio-demographic groups bear the greatest stigma burden, and 
assess the association between stigma and sustained HIV viral suppression. The Medical 
Monitoring Project measures characteristics of U.S. HIV-infected adults receiving care using a 
national probability sample. We used weighted data collected from June 2011 to May 2014 and 
assessed self-reported internalized stigma based on agreement with six statements. Overall, 79.1% 
endorsed ≥1 HIV-related stigma statements (n = 13,841). The average stigma score was 2.4 (out of 
a possible high score of six). White males had the lowest stigma scores while Hispanic/Latina 
females and transgender persons who were multiracial or other race had the highest. Although 
stigma was associated with viral suppression, it was no longer associated after adjusting for age. 
Stigma was common among HIV-infected adults in care. Results suggest individual and 
community stigma interventions may be needed, particularly among those who are <50 years old 
or Hispanic/Latino. Stigma was not independently associated with viral suppression; however, this 
sample was limited to adults in care. Examining HIV-infected persons not in care may elucidate 
stigma’s association with viral suppression.
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Introduction
HIV-infected persons in the United States may experience HIV-related stigma, a social 
process where HIV-infected persons are assumed to possess negative traits [1], resulting in 
stereotyping, rejection, assigning personal blame for disease, and discrimination [2–4]. 
Internalized HIV-related stigma is when an HIV-infected person believes these negative 
assumptions are true about themselves [1]. Internalized stigma has been linked to poor 
antiretroviral treatment (ART) adherence [5, 6], avoiding disclosure of HIV status [7, 8], 
depression [7, 9, 10], and poor physical and mental health [9, 10]. Reducing stigma is an 
objective of the National HIV/AIDS Strategy [11]. Despite this, we lack national estimates 
of the prevalence of HIV-related stigma among HIV-infected adults in medical care, nor do 
we have national data on which demographic groups have the highest internalized HIV 
stigma or whether stigma is associated with other social determinants of health. Determining 
whether HIV-related internalized stigma varies by socio-demographic factors, such as 
gender, race/ethnicity, education, or social support satisfaction, may be useful to direct 
stigma reduction efforts to those with the greatest burden.
Adherence to ART is essential for achieving viral suppression, a key indicator of treatment 
success for HIV-infected persons [12–16], and many studies have measured the relationship 
between stigma and ART adherence. A systematic review found that three out of four studies 
supported a relationship between internalized stigma and ART adherence, though in one 
study the relationship was attenuated in multivariate analyses [10]. However, few studies 
have measured the association between stigma and viral suppression. A study of unstably 
housed HIV-infected persons found no relationship between stigma and viral suppression, 
but it is unknown if the same result would remain among a representative sample of HIV 
patients in the United States. Our analysis will fill this gap in the literature by assessing the 
association between internalized HIV stigma and viral suppression using matched medical 
record and interview data from adults receiving HIV care.
The objectives of this analysis were to: (1) determine the national prevalence of HIV-related 
internalized stigma, (2) describe which socio-demographic groups had the highest 
proportions of HIV-related internalized stigma, (3) describe the social determinants of health 
associated with stigma, and (4) assess the relationship between HIV-related internalized 
stigma and sustained viral suppression after controlling for confounders.
Methods
Medical Monitoring Project
The Medical Monitoring Project (MMP) is an HIV surveillance system designed to collect 
nationally representative estimates of behavioral and clinical characteristics of HIV-infected 
adults receiving medical care in the United States. Detailed MMP methods, including 
weighting procedures, have been described elsewhere [17]. Briefly, MMP used a three-stage, 
probability-proportional-to-size sampling method, which sampled states and territories, then 
outpatient facilities providing HIV care, and finally HIV-infected adults 18 years or older 
who reported at least one medical care visit in a participating facility. This analysis used data 
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from the 2011–2013 cycles. Data were collected through face-to-face and telephone 
interviews and medical record abstractions from June 2011 through May 2014.
All sampled jurisdictions participated in MMP. Facility response rates ranged from 83 to 
85% and patient response rates ranged from 49 to 55%. MMP data were weighted to account 
for unequal selection probabilities and facility and patient nonresponse. Although 
characteristics associated with nonresponse varied over time, the following characteristics 
were generally associated with nonresponse and informed weighting classes: facility size, 
private practice, younger age, black race, Hispanic ethnicity, and shorter time since HIV 
diagnosis.
In accordance with guidelines for defining public health research [18, 19], the Centers for 
Disease Control and Prevention (CDC) determined MMP was public health surveillance. 
Participating states, territories, and facilities obtained local Institutional Review Board (IRB) 
approval to conduct MMP, if required locally.
Measures
Internalized HIV-related stigma was measured using the modified six-item Internalized 
AIDS-related stigma scale [1], in which respondents rated their agreement with six 
statements (Table 1). The stigma questions refer to the respondent’s current attitude (e.g. “It 
is difficult to tell people about my HIV infection”). Respondents who did not answer all the 
stigma statements (n = 593) were excluded, leaving 13,841 persons included in the analysis. 
All “agree” responses were scored as “1”, “disagree” responses were scored as “0”, and 
neutral responses were scored as “0.5.” Responses were summed into a single score with a 
possible range of 0 (low stigma)–6 (high stigma). The stigma scale had acceptable internal 
consistency (Cronbach’s α = 0.78).
Socio-demographic and social determinants of health factors, such as race/ethnicity, gender, 
and insurance type, were based on self-report (Table 2). The gender identity variable 
combined self-reported sex at birth and gender identity. Intersex individuals were excluded 
from the analysis due to small sample size. Individuals who reported multiple racial 
identities or a race/ethnicity other than non-Hispanic white, non-Hispanic black, or 
Hispanic/Latino were categorized as “other/multiracial.” In order to determine which 
combination of race/ethnicity and gender groups experienced the greatest burden of stigma, 
we present the results stratified by each race/ethnicity and gender combination.
Sustained viral suppression was defined as all HIV viral load test results documented in 
medical records as undetectable or less than 200 copies/mL during the past 12 months. Self-
reported ART use and adherence was defined as a three-level categorical variable: not taking 
ART; taking ART, but not adherent; and taking ART, adherent. Adherence was defined as 
self-reported 100% adherence to all HIV medicine doses in the past 3 days.
Analytic Methods
First, we report the distribution of the responses to the six stigma statements and the 
distribution of the range of stigma scores using weighted percentages. We assessed whether 
average stigma scores varied among socio-demographic groups using one-way ANOVA 
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tests. Significance was defined as p < 0.05. Referent groups were determined by lowest 
average stigma score.
We used multivariate logistic regression models to assess the independent association 
between stigma and viral suppression. We used crude and adjusted prevalence ratios because 
our outcome was not rare. Stigma was modeled as a continuous variable because the 
relationship between stigma and viral suppression was linear. We assessed the following 
potential confounders: age, time since diagnosis, gender, race/ethnicity, poverty, and sexual 
orientation. Identified confounders were also tested as effect modifiers. If we found an 
independent association between stigma and sustained viral suppression, we would then test 
for mediators, such as ART adherence.
There were minor differences in the 2011 and the 2012/2013 stigma response options, where 
respondents could provide a “neutral” answer in 2011. To ascertain whether the inclusion of 
a “neutral” response option in 2011 influenced our results (>10% change in point estimates), 
we compared results from our final multivariable model using only 2011 data with that 
obtained using 2012 and 2013 data. If 2011 yielded significantly different results than 
2012/2013, we would either stratify results by cycle year or consider dropping the 2011 data 
from the analysis. We found an adjusted prevalence ratio [aPR] of 0.99 (95% confidence 
interval [CI] 0.99–1.01) for stigma in the full model using only 2011 data and an aPR of 
1.00 (95% CI 0.99–1.01) for the full model using 2012/2013 data. Because the stigma 
estimates did not meaningfully differ and the stigma score was not significantly associated 
with viral suppression in either model, we combined all cycle years for the final analysis.
All analyses accounted for the complex survey design and weights using PROC 
SURVEYFREQ, PROC SUR-VEYMEANS, and PROC SURVEYLOGISTIC in SAS 9.3 
(SAS Institute, Cary, NC), as well as PROC RLOGIST in SAS-callable SUDAAN (RTI 
International, Research Triangle Park, NC).
Results
Overall, 79.1% (95% CI 77.4–80.7) of HIV-infected adults receiving medical care endorsed 
at least one stigma statement. The average stigma score was 2.4 (95% CI 2.4–2.5) out of a 
possible score of 6. The distribution of responses to each stigma statement is shown in Table 
1, where 65.6% of persons agreed that it is difficult to tell others about their HIV infection 
and 58.8% reported hiding their HIV status from others. Figure 1 shows that 8.6% (95% CI 
8.0–9.2) of persons agreed and 18.9% (95% CI 17.3– 20.4) disagreed with every stigma 
statement.
Table 2 presents the population distribution and average stigma score and 95% CI by socio-
demographic and clinical characteristics. Among males, Hispanic/Latino (average = 2.6) and 
other/multiracial males (average = 2.6) had the highest stigma scores. Among females, 
Hispanic/Latina females had the highest average stigma scores (average = 3.0). Among 
transgender persons, other/multiracial transgender individuals had the highest stigma score 
(average = 3.4). Stigma scores were higher among persons who were younger than 50 years 
old compared to older persons, and those who had poorer social determinants of health, 
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including less education, suboptimal health insurance status, homelessness, poverty, recent 
incarceration, and dissatisfaction with social support. Persons with poorer clinical outcomes, 
including not taking or adhering to ART and not achieving sustained viral suppression also 
had higher stigma scores.
Table 3 reports the results of the crude and adjusted logistic regression models assessing the 
association between internalized stigma and sustained viral suppression. In the crude model, 
a higher stigma score was significantly associated with lower sustained viral suppression 
(crude prevalence ratio = 0.99). All potential confounders were assessed, but only age met 
our criteria for confounding. When age was added to the model, the stigma score was no 
longer significantly associated with sustained viral suppression (aPR = 0.99), indicating that 
age confounded the association. Further, inclusion of an interaction term for stigma and age 
indicated that age was not an effect modifier of the relationship between stigma and viral 
suppression (aPR = 1.0, 95% CI 1.0–1.0, p = 0.63, results not show in table). Since the 
relationship between stigma and sustained viral suppression was confounded by age, we did 
not test for any mediators, such as ART adherence. Overall, our results suggest that 
internalized stigma is not an independent predictor of viral suppression among persons 
receiving care for HIV.
Discussion
We present the first, to our knowledge, nationally representative prevalence estimates of 
internalized HIV-related stigma among HIV-infected adults in care. Average stigma scores 
among HIV-infected adults receiving HIV care (average = 2.4) were comparable to previous 
smaller studies using the same scale [1, 7, 20, 21], which ranged from 2.1 to 3.0 depending 
on the country; the U.S.-based studies found average stigma scores of 2.4 [1] and 2.1 [7]. 
Nearly eight out of ten persons receiving HIV care in the United States agreed with at least 
one stigma statement. Almost two-thirds said that it was difficult to tell others about their 
HIV infection, which could have implications for disclosing their HIV status to sex partners. 
This is consistent with previous literature that HIV-related stigma is associated with low 
disclosure of HIV status [7, 8].
Overall, women and transgender persons had higher stigma scores than men and, compared 
to non-Hispanic whites, all other racial/ethnic groups had higher stigma scores. Stratifying 
these estimates by combined race/ethnicity and gender groups revealed key differences. 
Among women, Hispanic/Latina women reported the highest average stigma scores, while 
non-Hispanic black women reported the lowest scores. Although the cell sizes are smaller, 
transgender persons identifying as other/multiracial reported the highest stigma scores 
overall, significantly higher than non-Hispanic white transgender persons. These racial/
ethnic and gender differences in stigma burden may help inform stigma reduction efforts 
from public health practitioners, policymakers, and clinicians by identifying key groups in 
need of intervention.
We also found that higher stigma scores were associated with several social determinants of 
health. The findings from this nationally representative sample are consistent with results 
from smaller studies that found that persons who reported lower education [22], poverty 
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[23], suboptimal health insurance [9], foreign born status [24], recent experiences with 
homelessness [8, 25], or incarceration [26] had higher stigma scores. This suggests that 
interventions to reduce stigma may need to consider the multiple challenges facing HIV-
infected persons who experience internalized stigma, but further work may be needed to 
elucidate the relationship between internalized stigma and poor social determinants of 
health.
One key finding from this analysis was that, after adjusting for age, there was no significant 
association between the stigma score and sustained viral suppression among persons 
receiving HIV care. Other studies have found a relationship between younger age and higher 
internalized stigma [4, 21], and some have hypothesized that this may be due to less 
knowledge of HIV [4]. Younger HIV-positive people are also less likely to adhere to ART 
[15, 27–29] and less likely to achieve viral suppression [27, 30]. Our results are consistent 
with this literature and contribute the finding that young age confounds the independent 
association between internalized stigma and sustained viral suppression among persons 
receiving HIV care. However, stigma may still be independently associated with other 
aspects of health among persons in care, such as adherence [6] and depression [10]. Our 
results suggest younger persons may be in need of tailored stigma-reduction interventions, 
for example those that address knowledge of HIV [4] and those designed to address stigma 
among youth [31].
Stigma scores were significantly higher among persons who were dissatisfied with their 
social support, an association supported by prior research [32]. Fearing rejection from 
family and friends can lead some HIV-infected people to not disclose their HIV status, 
which can deprive them of social support [2]. It may be helpful for persons experiencing 
internalized HIV-related stigma to be referred to HIV peer support groups. This may 
increase their social support [33], which has been associated with better quality of life [34], 
mental health [35], and adherence [36, 37] among HIV-infected persons.
Stigma reduction efforts may be needed to help normalize HIV at a community level and to 
help individuals who have internalized negative attitudes about having HIV. Previous 
interventions have had success in reducing internalized stigma. An intervention using videos 
and other technology that normalize HIV and empower HIV-infected women in the southern 
United States was effective in reducing internalized stigma and enhancing self-esteem and 
coping mechanisms [38]. Our findings suggest that other groups that have high risk of 
stigma, such as trans-gender or Hispanic/Latino individuals, may benefit from a similar 
tailored intervention. Another intervention that was effective in reducing internalized stigma 
emphasized skills-building in young adults recently diagnosed with HIV, including 
decreasing negative feelings towards oneself and others living with HIV, increased strategic 
disclosure of HIV to others, building supportive social networks, and building skills to 
combat HIV-related stigma [31]. Because we found that young age was related to higher 
stigma scores and poorer viral suppression, this intervention may benefit from adding an 
adherence component to help improve viral suppression among younger HIV-infected 
persons. Community-based interventions, such as anti-stigma media campaigns like CDC’s 
Let’s Stop HIV Together [39], can work to reduce stigma toward people living with HIV 
among the general population [40].
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Limitations and Strengths
There were some limitations to this analysis. First, the stigma and adherence measures were 
self-reported and subject to social-desirability and recall biases. Second, due to the design of 
MMP, our analysis was restricted to HIV-infected adults who were in care. Thus, we cannot 
extrapolate our findings to HIV-infected adults who are out of care. In particular, our finding 
that age confounds the association between internalized stigma and viral suppression may be 
limited to only those who are in care, as it is possible that stigma could affect viral 
suppression through lack of linkage to and engagement in care. In 2015, MMP changed its 
sampling methods to include HIV-infected persons who are not in care; therefore, MMP has 
the potential to examine stigma among HIV-infected persons not in care in future analyses. 
Furthermore, our findings are limited to internalized stigma, though there are other forms of 
stigma that could be associated with viral suppression [10, 23]. For example, externalized 
stigma, which includes fear of discrimination or negative reactions from others upon 
disclosing status, could influence a person’s decision to engage in care. In 2015, MMP 
started using a stigma scale that captures multiple stigma dimensions, so future MMP 
analyses may address these limitations. Third, the stigma statements have a current time 
frame, but viral suppression was based on the past 12 months, so it is unknown whether 
stigma and viral suppression were concurrent. Fourth, while significant differences in stigma 
scores were observed, the effect sizes were relatively small. However, the prevalence of 
internalized stigma was substantial among HIV-infected persons in care. Future work may 
examine whether differences in agreement with the stigma statements that make up the scale 
vary among specific subpopulations, which may produce information that could further 
inform development of stigma reduction interventions. Finally, while MMP’s overall 
response rate is lower than optimal, low response rates are not necessarily indicative of 
nonresponse bias, particularly when probabilistic samples are drawn from rigorously 
constructed frames and adjusted for nonresponse, as is the case for MMP data [41, 42].
Despite these limitations, the strengths of this analysis include the probability-based 
sampling methodology; a large, geographically diverse sample size; use of a previously 
validated stigma scale; and the linking of behavioral interview data with clinical information 
from medical records [43]. Finally, the MMP population was shown to share similar 
demographic characteristics with all HIV-diagnosed persons [43].
Internalized stigma continues to affect a substantial portion of HIV-infected persons in the 
United States, suggesting a need for individual and community-level stigma reduction 
interventions. Efforts to reduce stigma among HIV-infected persons may be tailored for 
specific populations such those who are younger; women, particularly Hispanic/Latina 
women; transgender; racial/ethnic minorities; or who have poorer social determinants of 
health. Future research may be helpful to understand the role that stigma plays among HIV-
infected individuals who are not in care.
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Fig. 1. 
Distribution of summed stigma scores among HIV-infected adults receiving care*, United 
States, Medical Monitoring Project, 2011–2013. *Limited to respondents who answered all 
six stigma questions
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Table 1
Distribution of responses to stigma statements among HIV-infected adults in care, United States, Medical 
Monitoring Project 2011–2013 (n = 13,841)
Question Agreea (Weighted%) Neutral (Weighted%) Disagreea (Weighted%)
It is difficult to tell people about my HIV infection 9064 (65.6) 268 (2.1) 4509 (32.3)
I hide my HIV status from others 8211 (58.8) 373 (3.0) 5257 (38.2)
I feel guilty that I am HIV-positive 4807 (34.5) 272 (2.1) 8762 (63.5)
I am ashamed that I am HIV-positive 4573 (32.9) 269 (2.1) 8999 (65.0)
Being HIV-positive makes me feel dirty 3164 (23.0) 279 (2.2) 10,398 (74.9)
I sometimes feel worthless because I am HIV-positive 3255 (23.6) 242 (1.9) 10,344 (74.6)
Limited to respondents who answered all stigma questions; Missing, n = 593
a
Response options changed by year. The 2011 scale had “strongly agree,” “agree,” “neutral,” “disagree,” and “strongly disagree; the 2012–2013 
scale had “agree” or “disagree”; “strongly agree” and “agree” options were combined and “strongly disagree” and “disagree” options were 
combined
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Table 2
Average stigma scores by socio-demographic and clinical characteristics among HIV-infected adults in care, 
United States, Medical Monitoring Project, 2011–2013 (n = 13,841)
Characteristic n
Weighted Column % (95% 
CI)
Average stigma score (μ 
(95%CI)) p value
Gender and race/Ethnicity groups
 Male
  Black/African American 3514 25.5 (21.4–29.6) 2.4 (2.3–2.4) 0.0046
  Hispanic/Latinoa 2151 14.3 (11.3–17.2) 2.6 (2.5–2.7) <0.0001
  White 3796 29.2 (24.1–34.3) 2.1 (2.0–2.3) Ref
  Other/Multiracial 468 3.5 (2.9–4.2) 2.6 (2.4–2.8) <0.0001
 Female
  Black/African American 2214 15.6 (12.7–18.9) 2.7 (2.6–2.8) Ref
  Hispanic/Latina 777 4.9 (3.3–6.5) 3.0 (2.8–3.1) 0.0019
  White 591 4.6 (4.0–5.2) 2.8 (2.5–3.0) 0.80
  Other/Multiracial 126 1.0 (0.7–1.2) 2.9 (2.5–3.4) 0.38
 Transgenderb
  Black/African American 93 0.7 (0.5–0.8) 2.6 (2.0–3.1) 0.26
  Hispanic/Latino 56 0.3 (0.2–0.4) 2.8 (2.3–3.4) 0.07
  White 30 0.2 (0.1–0.3) 2.0 (1.4–2.7) Ref
  Other/Multiracial 17 0.2 (0.1–0.2) 3.4 (2.5–4.4) 0.03
Age (years)
 18–29 1035 7.8 (7.0–8.5) 2.7 (2.5–2.9) <0.0001
 30–39 2070 15.5 (14.6–16.4) 2.7 (2.6–2.8) <0.0001
 40–49 4457 31.7 (30.9–32.8) 2.5 (2.4–2.6) <0.0001
 ≥50 6279 45.0 (44.0–46.0) 2.3 (2.2–2.3) Ref
Sexual identity
 Heterosexual 6858 48.4 (44.5–52.4) 2.7 (2.6–2.8) <0.0001
 Bisexual 1127 8.1 (7.4–8.7) 2.6 (2.4–2.7) <0.0001
 Homosexual, gay, or lesbian 5679 42.1 (38.1–46.2) 2.1 (2.0–2.2) Ref
 Other 177 1.4 (1.1–1.6) 2.5 (2.2–2.8) 0.02
Education
 <High school 2939 20.6 (18.5–22.7) 2.7 (2.6–2.8) <0.0001
 High school or equivalent 3769 27.1 (25.5–28.7) 2.5 (2.4–2.6) 0.0007
 >High school 7125 52.3 (49.1–55.5) 2.3 (2.2–2.4) Ref
Health insurance in past 12 months
 Private health insurance 3891 29.7 (26.4–33.0) 2.3 (2.2–2.5) Ref
 Public health insurance 7626 52.6 (59.6–55.7) 2.4 (2.4–2.5) 0.06
 Ryan White insurance or uninsured 2285 17.7 (14.8–20.6) 2.6 (2.5–2.7) 0.0002
Povertyc
 Above poverty level 7106 54.7 (51.4–57.9) 2.3 (2.3–2.4) Ref
 At or below poverty level 6232 45.3 (42.1–48.6) 2.6 (2.5–2.7) <0.0001
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Characteristic n
Weighted Column % (95% 
CI)
Average stigma score (μ 
(95%CI)) p value
Homelessnessd
 Homeless in past 12 months 1143 8.1 (7.5–8.9) 2.7 (2.5–2.9) 0.0008
 Not homeless in past 12 months 12,698 91.9 (91.1–92.6) 2.4 (2.4–2.5) Ref
Incarcerated in past 12 months
 Yes 669 4.9 (4.4–5.3) 2.6 (2.4–2.8) 0.04
 No 13,168 95.1 (94.7–95.6) 2.4 (2.4–2.5) Ref
Foreign born
 Born outside U.S. 1917 13.9 (12.2–15.6) 2.8 (2.7–2.9) <0.0001
 Born in U.S. 11,920 86.1 (84.4–87.8) 2.4 (2.3–2.5) Ref
Satisfaction with support from friends and family
 Very satisfied 8879 70.5 (69.3–71.6) 2.2 (2.1–2.2) Ref
 Somewhat satisfied 2526 20.0 (19.1–21.0) 3.0 (2.9–3.0) <0.0001
 Somewhat dissatisfied 561 4.4 (3.9–4.8) 3.3 (3.1–3.5) <0.0001
 Very dissatisfied 653 5.1 (4.6–5.6) 3.1 (2.9–3.3) <0.0001
Time since HIV diagnosis
 Diagnosed with HIV <5 years ago 2707 21.1 (20.2–22.1) 2.9 (2.8–3.0) <0.0001
 Diagnosed with HIV ≥5 years ago 11,131 78.9 (77.9–79.8) 2.3 (2.3–2.4) Ref
ART use and adherence
 Not taking ART 798 6.0 (5.5–6.6) 2.6 (2.4–2.8) 0.006
 Taking ART, Not Adherent 1559 11.1 (10.1–12.1) 2.8 (2.7–3.0) <0.0001
 Taking ART, Adherent 11,107 82.9 (81.7–84.0) 2.4 (2.3–2.4) Ref
Sustained viral suppression
 All viral load measures in the past year <200 copies/ml 9145 65.4 (64.0–66.9) 2.4 (2.3–2.5) Ref
 >1 viral load measure(s) in the past year ≥ 200 
copies/ml
4696 34.6 (33.1–36.0) 2.5 (2.5–2.6) 0.0009
Clinical status
 AIDS or CD4+ cell count 0–199 cells/μl (nadir) 9540 68.6 (67.2–70.0) 2.4 (2.3–2.5) Ref
 No AIDS and CD4+ cell count 200–499 cells/μl (nadir) 3233 23.9 (22.8–24.9) 2.5 (2.4–2.6) 0.0009
 No AIDS and CD4+ cell count ≥ 500 cells/μl (nadir) 1015 7.5 (6.9–8.1) 2.6 (2.4–2.7) 0.02
CI confidence interval
a
Hispanic/Latino/as might be of any race. Patients are classified in only one race/ethnicity category
b
Patients were classified as transgender if sex at birth and gender reported by patient were different, or if patient chose transgender in response to 
the question about self-identified gender
c
Poverty guidelines as defined by the Department of Health and Human Services (HHS). More information regarding the HHS poverty guidelines 
can be found at http://aspe.hhs.gov/poverty/faq.cfm
d
Living on the street, in a shelter, in a single-room-occupancy hotel, or in a car
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